- The FDA has granted 510(k) clearance to Becton, Dickinson And Company’s (NYSE:BDX) BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application.
- Staphylococcus aureus is a bacteria that causes various clinical diseases with potentially serious infections. BD Kiestra uses artificial intelligence software to interpret bacterial growth and release negative specimens.
- The imaging application automatically organizes specimens in meaningful worklists with minimal human interaction, enhancing microbiology laboratory efficiency and workflow.
- Also Read: Becton, Dickinson Shares Dip Despite Q2 Earnings Beat – Here Are The Details
- The FDA nod will enable medical laboratory scientists and technicians to spend more time on higher-value analysis, reducing the administrative burden on technicians.
- The application can evaluate single specimens or group together a large volume of plates.
- “The pandemic created significant and ongoing labor challenges in laboratories, and reading plates is a labor-intense, potentially error-prone process in microbiology,” said Nikos Pavlidis, vice president and general manager for Diagnostics at BD.
- Price Action: BDX shares are up by 0.17% to $251.50 in premarket on the last check Tuesday.
- Photo Via Company
Lumos Pharma Announced Oral Presentation Highlighting Data On 15 Subjects From OraGrowtH212 Trial Supportive Of Conclusions From Interim Data Analysis
Lumos Pharma, Inc. (NASDAQ: LUMO) announced today that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology (IMPE), held in Buenos Aires, Argentina, March 4-7, 2023.
